Both Neurogenic Detrusor Overactivity (NDO) and AD combine to place a tremendous burden on individuals with SCI. The authors hypothesized that by treating NDO, thereby reducing the frequency and severity of AD, quality of life (QoL) in this population can be improved.
This was a prospective, open-label study to assess the efficacy of onabotulinumtoxinA to reduce AD in individuals following SCI.This study has been registered at clinicaltrials.gov (NCT02298660).
Individuals with chronic (1-year post injury), traumatic SCI at or above the level of spinal segment T6 suffering from AD and NDO following SCI were assessed at baseline (i.e. screening for eligibility, #1) and one month post-treatment (#2).
All individuals underwent intradetrusor onabotulinumtoxinA injections (200 IU) to treat NDO. Assessments included urodynamics, 24-hour ambulatory blood pressure (BP) monitoring and two validated, standardized questionnaires, i.e. incontinence QoL (I-QoL) and AD health-related QoL (AD HR QoL). The I-QoL comprise 22 items over three domains, i.e. avoidance and limiting behavior (ALB), psychosocial impacts (PSI) and social embarrassment (SE). Each item can have a value on a 5-point scale from 1 (extremely) to 5 (not at all). The AD HR QoL utilizes symptoms characteristics of AD to subjectively score frequency and severity of AD episodes on a daily basis and upon bladder filling. Changes in BP and heart rate were recorded during urodynamic investigations to capture artificially induced AD. The 24-hour ambulatory BP monitoring was applied to detect spontaneous episodes of AD.
Objectively, onabotulinumtoxinA improved lower urinary tract function resulting in an increased cystometric capacity (from 339±217 to 519±212mL, p<0.001). Thus, onabotulinumtoxinA decreased maximum detrusor pressure during bladder filling (from 46±27 to 17±10cmH2O, p=0.018). Moreover, onabotulinumtoxinA reduced the severity of artificially induced AD during UDS#2 (ΔSBP from 48±25 to 35±30mmHg, p=0.008) as well as frequency (from 15±12 to 10±9, p=0.02) and severity (ΔSBP from 60±31 to 42±18mmHg, p<0.001) of spontaneous AD in daily life (ABPM#2).
Only minor complications, i.e. CD I or II occurred in 20 or 6 participants, respectively.
This result supports that onabotulinumtoxinA significantly ameliorates AD (i.e. during UDS and in daily life) in individuals with SCI. Thus, onabotulinumtoxinA not only is a successful second-line NDO treatment option but provides a substantial capacity to reduces AD-related long-term cardiovascular consequences in individuals living with spinal cord injury.
In conclusion, onabotulinumtoxinA not only reduces the frequency and severity of AD safely but also improves QoL for individuals living with SCI significantly
Presented by: Matthias Walter, International Collaboration on Repair Discoveries (ICORD), University of British Columbia, Vancouver, Canada
Co-Authors: Kran S L1, Nigro M K2, Stothers L2, Rapaport D2, Kavanagh A2, Krassioukov A V1
1. International Collaboration on Repair Discoveries (ICORD), University of British Columbia, Vancouver, Canada, 2. Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
Written by: Bilal Farhan, MD; Clinical Instructor, Female Pelvic Medicine and Reconstructive Surgery, University of California, Irvine Medical Center, Twitter: @Bilalfarhan79 at the 2018 ICS International Continence Society Meeting - August 28 - 31, 2018 – Philadelphia, PA USA